

Date: October 25, 2024

BSE Limited P J Towers, Dalal Street,

Mumbai – 400 001

Script Code: 543904 Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of Investor Conference Call for Q2 & H1 FY25 with Senior Management of Mankind Pharma Limited ("the Company")

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,

Bandra (E), Mumbai – 400 051

Pursuant to Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will host Investor Conference Call on Tuesday, November 5, 2024 at 06:00 p.m. (IST) for Q2 & H1 FY25.

Details of the Investor Conference Call are enclosed herewith.

The same are also being uploaded on website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

Pradeep Chugh Company Secretary and Compliance Officer

Encl.: As above



Mankind Pharma Limited <u>Earnings Call Invite | Q2 & H1 FY25</u>

You are cordially invited to the Earnings Call, Scheduled on **Tuesday**, **05**th **November 2024**, at **06:00** pm IST, To discuss Q2 & H1 FY25 business performance and results:

The details of the earnings call are as below:

Earnings Call Details		
Date	Tuesday, 05 th November 2024	
Time	06:00 pm – 07:00 pm IST	
Universal Dial-in	+91 22 6280 1102 +91 22 7115 8003	
International Toll-Free Numbers	USA : 18667462133 UK : 08081011573 Singapore : 8001012045 Hong Kong : 800964448	
Pre-register to avoid wait time	<u>Click here</u> to pre-register for the call and dial in directly without waiting for the operator.	

Management will be represented by:

- Mr. Rajeev Juneja Vice Chairman & Managing Director
- Mr. Sheetal Arora Chief Executive Officer & Whole Time Director
- Mr. Arjun Juneja Chief Operating Officer
- Dr. Sanjay Koul Chief Marketing Officer
- Mr. Ashutosh Dhawan Chief Financial Officer
- Mr. Prakash Agarwal President (Strategy)
- Mr. Abhishek Agarwal Head Investor Relations & AVP Strategy

For details, please contact:

Mankind Pharma Limited	Adfactors PR
Abhishek Agarwal	Snighter Albuquerque / Smit Shah
E: Investor.relations@mankindpharma.com,	E: <u>Snighter.albuquerque@adfactorspr.com</u> /
T: 011 – 46846700	smit.shah@adfactorspr.com, M: +91 9870789596